百济神州与MSN达成专利和解 泽布替尼仿制药不得在2037年前销售

每日经济新闻
20 Nov 2024

11月20日,百济神州美股发布临时公告,称2024年11月14日,百济神州有限公司的两家子公司BeiGene USA,Inc.和BeiGene Switzerland GmbH(与百济神州有限公司合称“百济神州”)与MSN Pharmaceuticals,Inc.和MSN Laboratories Private Ltd.(合称MSN)就与公司产品BRUKINSA(中文商品名:百悦泽,通用名:泽布...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10